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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to a 
combination of flaxseed oil and vitamin E and maintenance of the skin 
permeability barrier function pursuant to Article 13(5) of Regulation (EC) 
No 1924/2006
1 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following  an  application  from  Nutrilinks  Sarl,  submitted  pursuant  to  Article  13(5)  of  Regulation  (EC) 
No 1924/2006 via the Competent Authority of Belgium, the Panel on Dietetic Products, Nutrition and Allergies 
(NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to a combination 
of flaxseed oil and vitamin E and maintenance of the skin permeability barrier function. The food constituent that 
is the subject of the health claim is a combination of flaxseed oil and vitamin E. The Panel considers that the 
combination of flaxseed oil and vitamin E is sufficiently characterised. The claimed effect is “contributes to 
maintain skin permeability barrier function”. The target population proposed by the applicant is healthy adults 
with  dry  and  sensitive  skin.  Maintenance  of  the  permeability  barrier  function  of  the  skin  is  a  beneficial 
physiological effect. The applicant identified two published human intervention studies as being pertinent to the 
health claim. Owing to the very limited information provided regarding key methodological aspects, and to the 
important limitations of the statistical analysis performed, the Panel considers that no conclusions can be drawn 
from these studies for the scientific substantiation of the claim. The Panel concludes that a cause and effect 
relationship has not been established between the consumption of a combination of flaxseed oil and vitamin E 
and maintenance of the skin permeability barrier function. © European Food Safety Authority, 2012 
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SUMMARY 
Following an application from Nutrilinks Sarl, submitted pursuant to Article 13(5) of Regulation (EC) 
No 1924/2006 via the Competent Authority of Belgium, the Panel on Dietetic Products, Nutrition and 
Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim 
related to a combination of flaxseed oil and vitamin E and maintenance of the skin permeability 
barrier function. 
The scope of the application was proposed to fall under a health claim based on newly developed 
scientific evidence. 
The food constituent that is  the subject of the health claim is a combination of flaxseed oil and 
vitamin E. The Panel considers that the combination of flaxseed oil and vitamin E is sufficiently 
characterised. 
The  claimed  effect  is  “contributes  to  maintain  skin  permeability  barrier  function”.  The  target 
population  proposed  by  the  applicant  is  healthy  adults  with  dry  and  sensitive  skin.  The  Panel 
considers  that  maintenance  of  the  permeability  barrier  function  of  the  skin  is  a  beneficial 
physiological effect. 
The applicant identified two published human intervention studies as being pertinent to the health 
claim. 
Owing to the very limited information provided regarding key methodological aspects (i.e. baseline 
characteristics of the study groups, background diet, skin site tested, use of cosmetics, randomisation, 
sample  size  estimate,  primary  outcome,  methods  used  for  data  analysis),  and  to  the  important 
limitations of the statistical analysis performed (repeated measures and multiple testing not taken into 
account), the Panel considers that no conclusions can be drawn from these studies for the scientific 
substantiation of the claim. 
The Panel considers that no human studies have been provided from which conclusions can be drawn 
for the scientific substantiation of the claim. 
The  Panel  concludes  that  a  cause  and  effect  relationship  has  not  been  established  between  the 
consumption of a combination of flaxseed oil and vitamin E and maintenance of the skin permeability 
barrier function. 
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BACKGROUND 
Regulation (EC) No 1924/2006
4 harmonises the provisions that relate to nutrition and health claims , 
and establishes rules governing the Community authorisation of health claims made on foods . As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of  
this Regulation, are authorised in accordance with this Regulation , and are included in the lists of 
authorised claims provided for in Articles 13 an d 14 thereof. In particular,  Article 13(5) of this  
Regulation lays down provisions for the addition of claims (other than those referring to the reduction 
of disease risk and to chi ldren’s  development  and  health)  which  are  based  on  newly  developed 
scientific  evidence,  or  which  include  a  request  for  the  protection  of  proprietary  data,  to  the 
Community list of permitted claims referred to in Article 13(3). 
According to Article 18 of this Regulation, an application for inclusion in the Community list of 
permitted  claims  referred  to  in  Article  13(3)  shall  be  submitted  by  the  applicant  to  the  national 
competent authority of a Member State, which will make the application and any supplementary 
information supplied by the applicant available to the European Food Safety Authority (EFSA). 
STEPS TAKEN BY EFSA 
  The application was received on 24/02/2012. 
  The  scope  of  the  application  was  proposed  to  fall  under  a  health  claim  based  on  newly 
developed scientific evidence. 
  On 15/03/2012, during the validation process of the application, EFSA sent a request to the 
applicant to provide missing information. 
  The applicant provided the missing information on 19/04/2012. 
  The scientific evaluation procedure started on 23/04/2012. 
  On 31/05/2012, the Working Group on Claims of the NDA Panel agreed on a list of questions 
for the applicant to provide additional information to accompany the application, and the 
clock  was  stopped  on  04/06/2012, in compliance with Art. 18(3) of Regulation (EC) No 
1924/2006. 
  On 19/06/2012, EFSA received the requested information as submitted by the applicant and 
the clock was restarted. 
  During  its  meeting  on  04/07/2012,  the  NDA  Panel,  having  evaluated  the  data  submitted, 
adopted an opinion on the scientific substantiation of a health claim related to a combination 
of flaxseed oil and vitamin E and maintenance of the skin permeability barrier function. 
TERMS OF REFERENCE 
EFSA  is  requested  to  evaluate  the  scientific  data  submitted  by  the  applicant  in  accordance  with 
Article 16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an 
opinion on the scientific substantiation of a health claim related to: a combination of flaxseed oil and 
vitamin E and maintenance of the skin permeability barrier function. 
EFSA DISCLAIMER 
The  present  opinion  does  not  constitute,  and  cannot  be  construed  as,  an  authorisation  for  the 
marketing of a combination of flaxseed oil and vitamin E, a positive assessment of its safety, nor a 
                                                       
4  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. Flaxseed oil and vitamin E and maintenance  
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decision on whether a combination of flaxseed oil and vitamin E is, or is not, classified as a foodstuff. 
It should be noted that such an assessment is not foreseen in the framework of Regulation (EC) No 
1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006. Flaxseed oil and vitamin E and maintenance  
of the skin permeability barrier function  
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address: Nutrilinks Sarl - Chemin de Beau-rivage 7 - Case postale 96 CH-
1000 Lausanne 21 - Switzerland. 
Food/constituent as stated by the applicant 
According to the applicant, flaxseed oil (1.11 g/day of α-linolenic acid) and vitamin E (10 mg/day) in 
a food supplement. 
Health relationship as claimed by the applicant 
According to the applicant, the claimed effect is “contributes to maintain skin permeability barrier 
function”. 
Wording of the health claim as proposed by the applicant 
The applicant has proposed the following wording for the health claim: “contributes to maintain skin 
permeability barrier function”. 
Alternative wordings proposed by the applicant: “contributes to skin hydration”, “helps to protect skin 
from dryness”, “helps to limit skin drying”, “helps to prevent skin drying”, “helps to increase skin 
hydration”,  “helps  to  increase  skin  hydration  of  dry  skin”,  “helps  to  reduce  skin  irritation”, 
“contributes to reduce skin redness”, “helps to reduce skin sensitivity”. 
Specific conditions of use as proposed by the applicant 
According to the applicant, the target population is healthy adults with dry and sensitive skin. The 
applicant has proposed an intake of four capsules per day during 12 consecutive weeks. 
ASSESSMENT 
1.  Characterisation of the food/constituent 
The food constituent that  is the subject of the health claim is a combination of flaxseed oil and 
vitamin E. The food constituent is available in the form of soft gel capsules. Each capsule consists of 
flaxseed oil (555 mg), vitamin E (d-α-tocopherol) (2.5 mg), and other ingredients (gelatine, glycerol, 
rosemary extract and titanium dioxide). 
The  fatty  acid  composition  of  flaxseed  oil  together  with  its  complete  specifications  have  been 
provided by the applicant: 2-8 % palmitic acid (C16:0), 2-6 % stearic acid (C18:0), 12-25 % oleic acid 
(C18:1, n-9), 10-20 % linoleic acid (C18:2, n-6), 45-64 % α-linolenic acid (C18:3, n-3) and 0-2 % 
erucic acid (C22:1, n-9). These fatty acids can be analysed in foods by established methods. 
The specifications of vitamin E, which is derived from sunflower oil, have been provided by the 
applicant. Vitamin E can be analysed in foods by established methods. 
Information  pertaining  to  the  manufacturing  process  and  control  specifications  of  the  finished 
product, to batch-to-batch variability and to stability data has been provided by the applicant. 
The Panel considers that the food constituent, a combination of flaxseed oil and vitamin E, which is 
the subject of the health claim, is sufficiently characterised. Flaxseed oil and vitamin E and maintenance  
of the skin permeability barrier function  
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2.  Relevance of the claimed effect to human health 
The  claimed  effect  is  “contributes  to  maintain  skin  permeability  barrier  function”.  The  target 
population proposed by the applicant is healthy adults with dry and sensitive skin. 
Skin is the outer barrier of the body and provides protection from exposure to harmful irritants and 
potentially pathogenic microorganisms. An impairment of the permeability barrier function of the skin 
leads to water loss from the stratum corneum and to skin dehydration. The associated symptoms 
include roughness of the skin with visible scaling and flaking, itching, and reduced resistance to 
shearing  forces.  Maintenance  (i.e.  reduced  loss)  of  the  permeability  barrier  function  of  the  skin 
protects the skin against dehydration. 
The Panel considers that maintenance of the permeability barrier function of the skin is a beneficial 
physiological effect. 
3.  Scientific substantiation of the claimed effect 
The applicant performed a literature search in PubMed, ScienceDirect, Blackwell Synergy, Wiley 
InterScience, Mary Ann Liebert, Scirus, IBIDS, SciFinder Scholar, Pascal and SCOPUS. The time 
period considered was from January 2008 to May 2011. 
The following key words were used alone or in combination: [“flaxseed oil” OR “omega 3 fatty 
acids” OR “α-linolenic acid” AND “vitamin E”] AND [“skin” OR “hydration” OR “moisturization” 
OR  “epidermis”  OR  “fibroblast”  OR  “keratinocyte”  OR  “TEWL”  OR  “dry  skin”  OR  “barrier 
functions” OR “sensitivity” OR “irritation”]. The inclusion criteria for selecting pertinent publications 
were studies performed with a combination of α-linolenic acid from flaxseed oil and vitamin E. No 
exclusion criteria were applied.  
The applicant identified two published human intervention studies as being pertinent to the health 
claim. 
In a randomised, double-blind, placebo-controlled study, De Spirt et al. (2009) investigated the effect 
of 2.2 g/day of flaxseed oil plus 10 mg/day of vitamin E vs. 2.2 g of borage oil plus 10 mg/day of 
vitamin E vs. 2.2 g/day of placebo (~60 % medium chain fatty acids and ~40 % non-identified fatty 
acids) for 12 weeks in 45 (n=15 subjects per group) healthy, non-smoking females (age 18-65 years; 
BMI 18-25 kg/m
2) with dry skin defined as a corneometer value of <40 arbitrary units. The exclusion 
criteria  were  pregnancy  and  breast-feeding,  history  of  fat  malabsorption,  liver  diseases,  diseases 
presenting  with  lipid  metabolism,  photosensitising  disorders,  and  intake  of  lipid  or  vitamin 
supplements or any other medication. The flaxseed oil used in the study had a similar fatty acid 
composition as the flaxseed oil which is the subject of the health claim. Following EFSA’s request for 
information on the demographic characteristics for each of the study groups at baseline, and on the 
background diet of the study participants, the applicant acknowledged that this information was not 
available. Water-holding capacity (measured by corneometry), transepidermal water loss (measured 
by TEWA-Meter TM 300
®), reddening (measured by chromametry), capillary blood flow (measured 
by Laser-Doppler-Flowmetry), evaluation of the skin surface (i.e. roughness, scaling, smoothness, 
wrinkles) and blood fatty acid composition were assessed at day 0, week 6 and week 12. Reddening 
and capillary blood flow were assessed after exposure to an irritant (nicotinate). Following EFSA’s 
request for information on the skin area tested and on whether cosmetics or ointments were allowed to 
be used on the tested area during the study, the applicant acknowledged that this information was not 
available.  No  information  was  provided  in  the  publication  regarding  the  method  used  for 
randomisation. It was also unclear how sample size was estimated or which outcome was the primary 
outcome of the study. In addition, the statistical methods used for data analysis were poorly described 
and  results  for  direct  comparisons  of  the  study  groups  with  respect  to  changes  in  the  outcome 
variables  of  interest  were  not  reported.  Upon  EFSA’s  request  for  clarification,  the  applicant Flaxseed oil and vitamin E and maintenance  
of the skin permeability barrier function  
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acknowledged that no additional information was available on these points. Owing to the very limited 
information provided regarding key methodological aspects (i.e. baseline characteristics of the study 
groups,  background  diet,  skin  site  tested,  use  of  cosmetics,  randomisation,  sample  size  estimate, 
primary outcome, methods used for data analysis), the Panel considers that no conclusions can be 
drawn from this study for the scientific substantiation of the claim. 
Neukam et al. (2011) conducted a 12-week double-blind study in 26 non-smoking females (age 18-65 
years; BMI 18-25 kg/m
2) who received daily either four capsules of flaxseed oil (2.2 g/day) plus  
vitamin E (15.4 mg/day) or four capsules of safflowerseed oil (2.2 g/day) (n=13 subjects per group). 
The exclusion criteria were history of malabsorption, liver diseases or disorders of lipid metabolism, 
pregnancy  or  lactation.  Subjects  were  requested  not  to  take  any  medication,  vitamins  or  other 
nutritional  supplements  and  to  refrain  from  using  any  cosmetic  treatment  in  the  test  area  (inner 
forearm) or from extensively sunbathing in the month before and during the study. The flaxseed oil 
used in the study had a similar fatty acid composition to the flaxseed oil which is the subject of the 
health claim. Following EFSA’s request for information on the demographic characteristics for each 
of the study groups at baseline, and on the background diet of the study participants, the applicant 
acknowledged  that  this  information  was  not  available.  Erythema  formation  (measured  by 
chromametry), capillary blood flow (measured by Laser-Doppler-Flowmetry), skin surface structure 
(i.e. roughness, scaling, smoothness, wrinkles), water-holding capacity (measured by corneometry), 
transepidermal water loss (measured by TEWA-Meter TM 300
®) and blood fatty acid composition 
were assessed at baseline and weeks 6 and 12. Erythema formation and capillary blood flow were 
assessed after exposure to an irritant (nicotinate). No information was provided in the publication 
regarding the method used for randomisation. It was also unclear how sample size was estimated or 
which outcome was the primary outcome of the study. Upon EFSA’s request for clarification, the 
applicant acknowledged that no additional information was available on these points. Within group 
comparisons  between  baseline  and  each  time  point  were  performed  using  the  non-parametric 
Wilcoxon signed-rank test. Between-group comparisons of changes from baseline at each time point 
were performed using the Wilcoxon rank sum test. The Panel notes that the statistical methods used 
for the data analysis did not take into account repeated measures or multiple testing. Upon EFSA’s 
request for clarification, the applicant acknowledged that no additional information was available on 
these points. Owing to the very limited information provided regarding key methodological aspects 
(i.e.  baseline  characteristics  of  the  study  groups,  background  diet,  randomisation,  sample  size 
estimate,  primary  outcome),  and  to  the important limitations of the statistical analysis performed 
(repeated measures or multiple testing not taken into account), the Panel considers that no conclusions 
can be drawn from this study for the scientific substantiation of the claim. 
The Panel considers that no human studies have been provided from which conclusions can be drawn 
for the scientific substantiation of the claim. 
The  Panel  concludes  that  a  cause  and  effect  relationship  has  not  been  established  between  the 
consumption of a combination of flaxseed oil and vitamin E and maintenance of the skin permeability 
barrier function. 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
 
  The food constituent, a combination of flaxseed oil and vitamin E, which is the subject of the 
health claim, is sufficiently characterised. 
  The claimed effect is “contributes to maintain skin permeability barrier function”. The target 
population  as  proposed  by  the  applicant  is  healthy  adults  with  sensitive  and  dry  skin. 
Maintenance of the permeability barrier function of the skin  is a beneficial physiological 
effect.  Flaxseed oil and vitamin E and maintenance  
of the skin permeability barrier function  
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  A  cause  and  effect  relationship  has  not  been  established  between  the  consumption  of  a 
combination of flaxseed oil and vitamin E and maintenance of the skin permeability barrier 
function.  
DOCUMENTATION PROVIDED TO EFSA 
Health claim application on a combination of flaxseed oil and vitamin E and maintenance of the skin 
permeability barrier function  pursuant to Article  13(5) of Regulation (EC) No 1924/2006 (Claim 
serial No: 0332_BE). February 2012. Submitted by Nutrilinks Sarl. 
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